BXM Wealth LLC Cuts Stock Position in Johnson & Johnson $JNJ

BXM Wealth LLC cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 94.1% in the 1st quarter, Holdings Channel.com reports. The fund owned 4,278 shares of the company’s stock after selling 67,962 shares during the period. BXM Wealth LLC’s holdings in Johnson & Johnson were worth $1,046,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in JNJ. Sierra Capital LLC increased its holdings in shares of Johnson & Johnson by 0.5% in the 4th quarter. Sierra Capital LLC now owns 8,144 shares of the company’s stock worth $1,685,000 after purchasing an additional 41 shares in the last quarter. Beaird Harris Wealth Management LLC lifted its stake in shares of Johnson & Johnson by 1.8% in the 4th quarter. Beaird Harris Wealth Management LLC now owns 2,422 shares of the company’s stock worth $501,000 after purchasing an additional 42 shares during the period. Broadleaf Partners LLC raised its position in Johnson & Johnson by 0.6% in the fourth quarter. Broadleaf Partners LLC now owns 7,348 shares of the company’s stock worth $1,521,000 after acquiring an additional 43 shares during the period. Jessup Wealth Management Inc raised its holdings in Johnson & Johnson by 0.6% in the 4th quarter. Jessup Wealth Management Inc now owns 7,574 shares of the company’s stock worth $1,567,000 after purchasing an additional 44 shares during the period. Finally, Plancorp LLC lifted its position in shares of Johnson & Johnson by 0.3% during the 4th quarter. Plancorp LLC now owns 15,889 shares of the company’s stock valued at $3,288,000 after buying an additional 45 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Activity

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the firm’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the transaction, the executive vice president directly owned 114,288 shares in the company, valued at $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Stock Performance

JNJ stock opened at $253.76 on Thursday. The firm has a 50-day simple moving average of $232.26 and a two-hundred day simple moving average of $230.68. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. Johnson & Johnson has a one year low of $154.21 and a one year high of $259.90. The firm has a market cap of $610.86 billion, a price-to-earnings ratio of 29.34, a PEG ratio of 2.49 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The business had revenue of $24.06 billion for the quarter, compared to the consensus estimate of $23.60 billion. During the same period in the prior year, the firm posted $2.77 earnings per share. The business’s quarterly revenue was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, equities analysts forecast that Johnson & Johnson will post 11.57 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th were given a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. The ex-dividend date of this dividend was Tuesday, May 26th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s payout ratio is currently 61.97%.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on JNJ. Royal Bank Of Canada restated an “outperform” rating and set a $265.00 target price on shares of Johnson & Johnson in a research note on Wednesday, April 15th. Morgan Stanley set a $283.00 price target on shares of Johnson & Johnson in a research report on Wednesday, April 15th. Citigroup boosted their price objective on Johnson & Johnson from $274.00 to $285.00 and gave the stock a “buy” rating in a research note on Tuesday, April 7th. Guggenheim increased their target price on shares of Johnson & Johnson from $266.00 to $270.00 and gave the company a “buy” rating in a research note on Friday, June 26th. Finally, Sanford C. Bernstein raised their price target on Johnson & Johnson from $225.00 to $251.00 and gave the stock a “market perform” rating in a research note on Wednesday, April 15th. Twenty analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $256.70.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson is strengthening its cancer franchise with positive European regulatory news for Tecvayli in combination with Darzalex SC, plus a planned acquisition of Firefly Bio to expand its oncology pipeline. Johnson & Johnson (JNJ) Expands Cancer Pipeline As Talc Verdict Eases One Risk
• Positive Sentiment: Management reiterated that J&J is prioritizing cancer and neuroscience rather than entering the obesity drug market, which signals a disciplined capital-allocation strategy and a clearer long-term growth plan. Johnson & Johnson (JNJ): Focused on Cancer and Neuroscience as a Top Dividend Aristocrat Stock to Buy
• Positive Sentiment: J&J is being featured by multiple outlets as a top dividend and income stock, and technical commentary says the shares are breaking out past a buy point, which may be encouraging momentum-oriented investors. J&J’s Innovative Medicine Business in Q2: Here’s What to Watch
• Neutral Sentiment: Analysts are focusing on upcoming Q2 Innovative Medicine results, with Stelara biosimilar pressure expected to offset some growth from newer therapies; investors may be waiting for earnings confirmation before pushing the stock higher. J&J’s Innovative Medicine Business in Q2: Here’s What to Watch
• Neutral Sentiment: Recent market coverage notes that J&J has already had a strong one-year rally, so some investors are now weighing whether the valuation still offers upside from here. Johnson & Johnson (JNJ) Stock After 73% One-Year Rally Is There Value Left

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.